SignalXSignalX

Kenvue (KVUE) Q3 2025 10-Q Quarterly Report

Filed: Nov 3, 2025Period ending Sep 28, 2025
Health Care
Perfumes, Cosmetics & Other Toilet PreparationsSEC EDGAR
Kenvue Overview

Kenvue (KVUE) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 28, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Kenvue Q3 2025 10-Q Analysis

Management Discussion & Analysis

  • • Quarterly revenue $3.76B, down 3.5% YoY ($135M decrease from $3.9B)
  • • Gross profit margin up 59.1% vs 58.5% YoY; operating income down 3.8%
  • • Skin Health & Beauty worst performer: sales down 3.2%, adjusted operating income down 28.3%
  • • Essential Health best performer: adjusted operating income up 5.5% despite 3.3% sales decline
  • • Operating cash flow up 37.6% YoY to $1.34B; increased investing outflow to $361M; dividend paid $1.18B in 9 months
  • • Management approved merger with Kimberly-Clark to complete in 2H 2026; faces acetaminophen regulatory risks impacting Tylenol sales

Risk Factors

  • • Newly added risk: Transaction financing increasing K-C’s debt, potentially reducing liquidity and flexibility before closing
  • • Most materially updated risk: $1,136M termination fee added if Transaction terminated under certain conditions, increasing financial exposure
  • • Regulatory risk: Transaction requires multiple approvals; regulatory conditions or delays may impose costs or restrict combined company’s operations
  • • Operational risk: Management distraction and key employee loss risks amid Transaction pendency threatening business continuity and integration
  • • Financial risk: Post-Transaction indebtedness could impair debt service, causing liquidity stress and forcing asset sales or capital raises

Kenvue Q3 2025 Quarterly Financials
XBRL

Revenue

$3.8B

▼ -3.5% YoY▼ -2.0% QoQ

Net Income

$398M

▲ +3.9% YoY▼ -5.2% QoQ

Net Margin

10.6%

▲ +75bp YoY▼ -37bp QoQ

Source: XBRL data from Kenvue Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Kenvue Quarterly Reports

Q2 2025 10-Q

Get deeper insights on Kenvue

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.